Capvaxive

News

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.

News

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.

News

FDA says yes to MSD’s 21-valent adult pneumococcal jab

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults.

MSD takes on Pfizer's Prevnar with new Capvaxive approval

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

FDA says yes to MSD’s 21-valent adult pneumococcal jab

Zymeworks cuts deal to buy Theravance for $929m in cash

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks